Customizing maintenance dosing for each patient helps make vitamin B12 therapy more effective
N.KennellyJ
Nevertheless, based on the promising pre-clinical and early-phase clinical trial findings in the colorectal cancer setting [12, 13, 32, 151], a Chinese phase III trial aiming to evaluate the effectiveness of combing high dose IV VitC (1.5 g/kg) with FOLOX +/ bevacizumab versus treatment with FOLFOX +/ bevacizumab alone as first-line therapy in patients with recurrent or advanced colorectal cancer is currently ongoing (ClinicalTrials.gov Identifier: NCT02969681, Table 3, recruiting status unclear)
The trial also identified potentially serious side effects in the semaglutide group, which are also typical for GLP-1 receptor agonists
This dual-compound approach leverages different receptor affinities to distribute metabolic load across pathways, potentially reducing peak side-effect intensity while sustaining weight-loss efficacy
It also screens for underlying conditions that could sabotage your success post-op
